DeutschNewstral
Article
jdsupra.com on 2018-06-22 00:53
FDA and Life Sciences FDA Finalizes Guidances for “Consistent Communications” and Payor Communications
Related news
- FDA Finalizes Guidance on Payor Communicationsjdsupra.com
- Guidances galore: FDA finalizes multiple digital health guidance documentsjdsupra.com
- FDA finalizes two guidances clarifying DSCSA enforcement exemptions and issues product identifier Q&Ajdsupra.com
- FDA guidances promote greater communication to payors about medical product value, clarify CFL communicationsjdsupra.com
- Blog: FDA Finalizes Two Guidance Documents Regarding Medical Product Communicationsjdsupra.com
- New FDA Biosimilar Guidances and Proposed Rulejdsupra.com
- FDA Releases Two Draft Guidances on REMSjdsupra.com
- FDA Issues Guidance on Drug and Device Manufacturer Communications: Part II – Medical Product Communications that are Consistent with the FDA-Required Labelingjdsupra.com
- FDA Releases Two Guidances for Innovative Drug Developmentjdsupra.com
- FDA Issues Two Product-Specific Guidances for Chloroquine Phosphate and Hydroxychloroquine Sulfate Drug Developersjdsupra.com
- Four new FDA guidances and proposed rule advance biosimilars policy frameworkjdsupra.com
- FDA Updates Digital Health Guidances to Align with 21st Century Cures Actjdsupra.com
- FDA Finalizes New Definition of Biological Productjdsupra.com
- FDA Finalizes Nutrition Labeling Guidance Documentsjdsupra.com
- FDA Finalizes Data Integrity Guidance, With Some Noteworthy Changesjdsupra.com
- FDA Finalizes Guidance on Public Warning and Notification of Recallsjdsupra.com
- Medical Device Developments: FDA Finalizes Four 510(k) Guidance Documentsjdsupra.com
- FDA Finalizes Guidance on Special 510(k) Pathwayjdsupra.com
- FDA releases four final guidances on the 510(k) program; Special 510(k) guidance confirms new approach to eligibility and broader potential for IVDsjdsupra.com
- Confidential FDA Communications as Prior Art in Hatch-Waxman Litigationjdsupra.com